<DOC>
	<DOCNO>NCT02932137</DOCNO>
	<brief_summary>The objective clinical study evaluate potential effect anti-infection low-does IL-2 patient SLE .</brief_summary>
	<brief_title>Anti-infection Low-does IL-2 SLE</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE ) chronic autoimmune syndrome affect various organs.Many feel glucocorticoid immunosuppressor standard therapy patient SLE . While improve risk infection among SLE patient . A novel therapy treat SLE low-does IL-2 identify recently . IL-2 also use virus infect . So hypothesized low-dose IL-2 could reduce risk infection SLE patient . Methods : A total SLE patient ( n=30 ) divide two group randomly . One received standard therapy , another one administrate low-does IL-2 plus standard therapy.Each patient treat low-dose IL-2 . The end point clinical immunologic response . Expected Results : This trail wlii provide clinical basic profe low-dose IL-2 plus standard therapy low infection risk SLE patient .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Meet American College Rheumatology criterion diagnosis SLE . Under standard treatment ( ≥ 2 month ) time inclusion Background treatment fail control flare permit prednisone taper With least one follow manifestation : thrombocytopenia , diseaseassociated rash , mouth ulcer , noninfectious type fever , active vasculitis , renal disorder ( proteinuria &gt; 0.5g/day ) , neuropsychiatric SLE . Positive least one follow laboratory test : ANA &gt; 1:160 , antidsDNA , immunoglobulin &gt; 20g/L , decrease C3 C4 , leukopenia &lt; 3×10^9/L , thrombocytopenia &lt; 100×10^9/L ; SLE disease activity index ( SLEDAI ) ≥ 8 . Negative HIV test . Negative hepatitis B C virus . Written inform consent form . Sever chronic liver , kidney , lung heart dysfunction ; ( heart failure ( ≥ grade III NYHA ) , hepatic insufficiency ( transaminases &gt; 3N ) ) Serious infection bacteremia , sepsis ; Cancer history cancer cure less five year ( except situ carcinoma cervix Basocellular carcinoma ) ; Highdose steroid pulse therapy ( &gt; 1.5mg/kg ) IV bolus corticosteroid last 2 month . History administration rituximab biologics ; Purified protein derivative ( tuberculin ) &gt; 10mm Mental disorder chronic illness drugabuse could interfere ability comply protocol give information ; Inability comply IL2 treatment regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>SLE , IL-2</keyword>
</DOC>